Literature DB >> 23147924

Prostate cancer: Time for active surveillance of intermediate-risk disease?

Hashim U Ahmed1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23147924     DOI： 10.1038/nrurol.2012.213

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry.

Authors:  Gerard P McVey; Sean McPhail; Sarah Fowler; Gregor McIntosh; David Gillatt; Chris C Parker
Journal:  BJU Int       Date:  2010-10       Impact factor: 5.588

2.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

Review 3.  Active surveillance in men with localized prostate cancer: a systematic review.

Authors:  Issa J Dahabreh; Mei Chung; Ethan M Balk; Winifred W Yu; Paul Mathew; Joseph Lau; Stanley Ip
Journal:  Ann Intern Med       Date:  2012-02-20       Impact factor: 25.391

4.  Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Authors:  Rebecka Arnsrud Godtman; Erik Holmberg; Ali Khatami; Johan Stranne; Jonas Hugosson
Journal:  Eur Urol       Date:  2012-09-05       Impact factor: 20.096

5.  Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Authors:  Meelan Bul; Roderick C N van den Bergh; Xiaoye Zhu; Antti Rannikko; Hanna Vasarainen; Chris H Bangma; Fritz H Schröder; Monique J Roobol
Journal:  BJU Int       Date:  2012-08-29       Impact factor: 5.588

Review 6.  Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?

Authors:  Hashim Uddin Ahmed; Manit Arya; Alex Freeman; Mark Emberton
Journal:  Lancet Oncol       Date:  2012-11       Impact factor: 41.316

7.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Authors:  Matthew R Cooperberg; Deborah P Lubeck; Maxwell V Meng; Shilpa S Mehta; Peter R Carroll
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

9.  Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.

Authors:  M T King; R Viney; D P Smith; I Hossain; D Street; E Savage; S Fowler; M P Berry; M Stockler; P Cozzi; P Stricker; J Ward; B K Armstrong
Journal:  Br J Cancer       Date:  2012-01-24       Impact factor: 7.640

10.  Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.

Authors:  Hashim U Ahmed; Richard G Hindley; Louise Dickinson; Alex Freeman; Alex P Kirkham; Mahua Sahu; Rebecca Scott; Clare Allen; Jan Van der Meulen; Mark Emberton
Journal:  Lancet Oncol       Date:  2012-04-17       Impact factor: 41.316
  10 in total
  4 in total

1.  Insignificant disease among men with intermediate-risk prostate cancer.

Authors:  Sung Kyu Hong; Emily Vertosick; Daniel D Sjoberg; Peter T Scardino; James A Eastham
Journal:  World J Urol       Date:  2014-09-27       Impact factor: 4.226

2.  Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.

Authors:  Jia-Xuan Qiu; Zhi-Wei Zhou; Zhi-Xu He; Ruan Jin Zhao; Xueji Zhang; Lun Yang; Shu-Feng Zhou; Zong-Fu Mao
Journal:  Drug Des Devel Ther       Date:  2015-01-07       Impact factor: 4.162

Review 3.  An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides.

Authors:  Jiang Cheng; Zhi-Wei Zhou; Hui-Ping Sheng; Lan-Jie He; Xue-Wen Fan; Zhi-Xu He; Tao Sun; Xueji Zhang; Ruan Jin Zhao; Ling Gu; Chuanhai Cao; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

4.  Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells.

Authors:  Zhi-Wei Zhou; Xing-Xiao Li; Zhi-Xu He; Shu-Ting Pan; Yinxue Yang; Xueji Zhang; Kevin Chow; Tianxin Yang; Jia-Xuan Qiu; Qingyu Zhou; Jun Tan; Dong Wang; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-03-12       Impact factor: 4.319
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.